Lanean...
Synergistic action of a RAF inhibitor and a dual PI-3 Kinase / mTOR inhibitor in thyroid cancer
PURPOSE: In thyroid cancer clinical trials, agents targeting VEGF receptors and RET, among other kinases, have led to partial responses but few complete or durable responses. The RAF-MEK-ERK and PI3K-AKT-mTOR signaling pathways are frequently activated in differentiated and medullary thyroid cancer...
Gorde:
| Argitaratua izan da: | Clin Cancer Res |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2011
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4828042/ https://ncbi.nlm.nih.gov/pubmed/21831957 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0933 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|